NCT07468630 2026-03-12
TRIUNITE-08
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Recruiting
Clinical Trials
34 trialsNCT05024968 2026-02-25
Sintilimab in Cancer of Unknown Primary
M.D. Anderson Cancer Center
Phase 2 Completed
NCT07394387 2026-02-06
Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT07005336 2026-01-30
A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer
TJ Biopharma Co., Ltd.
Phase 2 Active not recruiting
NCT07331883 2026-01-21
Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
Ruijin Hospital
Phase 2 Recruiting
NCT07351487 2026-01-20
Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT05348811 2026-01-06
HAIC Combined With Donafenib and Sintilimab for Unresectable ICC
Zhongda Hospital
Phase 2 Completed
NCT07120698 2026-01-05
CTONG 2508
Guangdong Association of Clinical Trials
Phase 2 Recruiting
NCT07309952 2025-12-30
SACTION 2501
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT05472948 2025-12-17
Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT06121505 2025-12-17
Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer
Sichuan University
Phase 2 Recruiting
NCT07179900 2025-12-11
Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
Hebei Medical University Fourth Hospital
Phase 2 Not yet recruiting
NCT07263386 2025-12-04
ARTEMIS-GC3
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT07157969 2025-12-01
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT07254858 2025-11-28
CISN-L
First Affiliated Hospital of Wenzhou Medical University
Phase 2 Not yet recruiting
NCT06493240 2025-11-25
NLCCRIT-LARC
Peking University People's Hospital
Phase 2 Completed
NCT05177068 2025-10-02
Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer
Henan Cancer Hospital
Phase 2 Active not recruiting
NCT07194005 2025-09-26
Remission
Fudan University
Phase 2 Recruiting
NCT07088731 2025-09-22
Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT06577194 2025-09-19
A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT05481476 2025-09-04
Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05026736 2025-08-17
Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT06031285 2025-07-23
Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
Sun Yat-sen University
Phase 2 Recruiting
NCT06050317 2025-07-22
Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT07053150 2025-07-08
CCGLC-018
Tongji Hospital
Phase 2 Not yet recruiting
NCT06356584 2025-06-26
Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT07040098 2025-06-26
STELLARIII
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT05161572 2025-06-18
NeoRacing
Fudan University
Phase 2 Terminated
NCT06013618 2025-06-17
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Sun Yat-sen University
Phase 2 Recruiting
NCT04548440 2025-06-12
Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients
Sun Yat-sen University
Phase 2 Completed
NCT07018063 2025-06-12
YOUNG-NEOS
Peking University People's Hospital
Phase 2 Not yet recruiting
NCT07007767 2025-06-06
Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT06928584 2025-04-15
Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer
Fudan University
Phase 2 Recruiting
NCT06860490 2025-03-26
HAIC Combined with Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
Fudan University
Phase 2 Recruiting